نبذة مختصرة : Paolo Rovero,1 Dennis Malvin Hernandez Malgapo,2 Adele Sparavigna,3 Ghislaine Beilin,4 Vincent Wong,5 Ma Purita Lao6 1Department of Neurofarba, Section of Pharmaceutical Sciences and Nutraceutics, University of Florence, Florence, Italy; 2Skinsoul Advanced Dermatology and Medical Aesthetics, Quezon City, Metro Manila, Philippines; 3DERMING S.r.l., Clinical Research and Bioengineering Institute, Milan, Italy; 4Beilin Consultant, Paris, France; 5Vindoc Aesthetics Academy, London, UK; 6Department of Dermatology, Makati Medical Center, Makati City, Metro Manila, PhilippinesCorrespondence: Dennis Malvin Hernandez Malgapo, Skinsoul Advanced Dermatology and Medical Aesthetics, Spark Place P. Tuazon Blvd, Cubao, Quezon City, Metro Manila, 1109, Philippines, Tel +63 928 6745699, Email dmhmalgapo@hotmail.comAbstract: A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH2), also known as KP1, formally derived from the C-terminal portion of serpin A1, an agent known as a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face. This review aims to provide a bio-inspired approach focusing on the latest scientific studies that describe the compound, as well as a comprehensive appraisal of laboratory and clinical tests on skincare formulations enriched with sA1-III.Keywords: KP1, prejuvenation, aging skin, aging well, anti-aging, SA1-III
Processing Request
No Comments.